Evidence map›Paper›PMID 38279719›Full record

ReviewCurrent cancer drug targets2024

Elucidating the Role of Pro-renin Receptors in Pancreatic Ductal Adenocarcinoma Progression: A Novel Therapeutic Target in Cancer Therapy.

Mohsen Aliakbarian, Gordon A Ferns, Mahmoud Mohamadzadeh Shabestari, Amir Mahmoud Ahmadzadeh, Aref Abdollahzade, Hoda Rahimi, Rozita Khodashahi, Mohammad-Hassan Arjmand

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Mohsen AliakbarianTransplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsDepartment of Biochemistry, Division of Medical, Brighton & Sussex Medical School, Brighton, UK.
Mahmoud Mohamadzadeh ShabestariDepartment of Cardiology, Emam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Mahmoud AhmadzadehTransplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Aref AbdollahzadeTransplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Hoda RahimiTransplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Rozita KhodashahiTransplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad-Hassan ArjmandTransplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRBrighton and Sussex Medical School · GBImam Reza Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a highly aggressive malignancy with a very poor prognosis. The 5- year survival in these patients is very low, and most patients develop drug resistance to current therapies, so additional studies are needed to identify the potential role of new drug targets for the treatment of pancreatic cancer. Recent investigations have been performed regarding the roles of pro-renin receptors (PRR) in the initiation and development of cancers. PRR is a component of the local renin-angiotensin system (RAS). Local tissue RAS has been known in diverse organ systems, including the pancreas. Various investigations have implicated that PRRs are associated with the upregulation of various signaling pathways, like the renin-angiotensin system pathway, PI3K/Akt/mTOR, and the Wnt-signaling pathways, to contribute to pathological conditions, including cancer. In this review, we presented an overview of the role of PRR in the progression of pancreatic adenocarcinoma.

Indexed as

Carcinoma, Pancreatic DuctalDisease ProgressionPancreatic NeoplasmsReceptors, Cell SurfaceAnimalsAntineoplastic AgentsHumansMolecular Targeted TherapyProrenin ReceptorRenin-Angiotensin SystemSignal TransductionAntineoplastic AgentsATP6AP2 protein, humanProrenin ReceptorReceptors, Cell Surfaceangiotensin convert enzyme.molecular signaling pathwayspancreatic ductal adenocarcinomapathwayspro-renin receptorRenin-angiotensin systemtarget therapy

Identifiers

PMID38279719
OpenAlexW4391253103

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.